New Combination Treatment for BRAF-Mutant Metastatic Colorectal Cancer
Understanding BRAF Mutation in Colorectal Cancer
A recent study has evaluated the effectiveness of a novel combination treatment for patients diagnosed with BRAF-mutant metastatic colorectal cancer. Approximately ten percent of individuals with metastatic colorectal cancer possess the BRAF mutation, which is associated with a poor prognosis. Initial therapies for this specific cancer subtype often yield disappointing outcomes, and subsequent treatment options demonstrate minimal impact.
Challenges with Current Treatments
Recent findings indicate that solely inhibiting the BRAF-mutated pathway during treatment is insufficient, which accounts for the limited clinical efficacy observed with existing BRAF-inhibiting therapies. However, studies have shown that BRAF inhibitors may be more effective when combined with an anti-EGFR monoclonal antibody, a conclusion supported by initial phase clinical trials. Additionally, the early trials of a triple combination therapy, incorporating a MEK inhibitor, have shown promise in treating BRAF-mutated metastatic colorectal cancer.
The BEACON CRC Trial
To investigate whether this triple therapy could enhance overall survival in patients with BRAF-mutated metastatic colorectal cancer, researchers launched the BEACON CRC trial (Binimetinib, Encorafenib, and Cetuximab Combined to Treat BRAF-Mutant Colorectal Cancer). The results of this trial are documented in the New England Journal of Medicine.
Trial Design and Patient Inclusion
BEACON CRC is a global, multi-center, phase three, randomized trial involving 665 patients with BRAF-mutated metastatic colorectal cancer who had previously failed either first or second-line treatments. Participants were assigned to one of three groups: a triple therapy group (receiving encorafenib, binimetinib, and cetuximab), a double therapy group (encorafenib and cetuximab), or a control group (standard treatment at the discretion of the investigator). This triple therapy was designed to optimally target the pathways associated with BRAF-mutant metastatic colorectal cancer.
Study Findings
The results revealed a significant 48% reduction in the risk of death for the triple therapy group compared to the control group. The median overall survival for the triple therapy participants was 9 months, in contrast to 5.4 months for those in the control group. Furthermore, the objective response rates were notably higher in the triple therapy group (26%) and the double therapy group (20%) than in the control group (2%). Patients in the triple and double therapy groups experienced longer durations before disease progression, with medians of 4.3 and 4.2 months, respectively, compared to 1.5 months in the control group.
Adverse Effects and Future Implications
The adverse effects reported across all groups were consistent with the expected drug profiles, and the combination therapy groups did not experience increased toxicity or mortality compared to the control group.
Early analysis from the BEACON CRC trial indicates that the triple therapy combination of encorafenib, binimetinib, and cetuximab leads to improved overall survival and higher objective response rates compared to standard treatments. These findings are encouraging for the development of future therapeutic strategies aimed at enhancing outcomes for patients with BRAF-mutated metastatic colorectal cancer. Continued investigation into the benefits of this triple therapy is warranted in forthcoming trials.
Author Information
Written by Maggie Leung, PharmD.
References
Kopetz, S., Grothey, A., Yaeger, R., Cutsem, E. V., Desai, J., Yoshino, T., … Tabernero, J. (2019). Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. New England Journal of Medicine. doi: 10.1056/nejmoa1908075
Novel treatment combination for patients with BRAF-mutant metastatic colorectal cancer. (2019, September 30). Retrieved from https://www.eurekalert.org/pub_releases/2019-09/vdio-ntc093019.php
Image by valelopardo from Pixabay.